Nanosonics Limited
Nanosonics Limited
Your view on NNCSF
Overview
What the company does, where it operates, and who runs it.
About Nanosonics Limited
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Michael C. Kavanagh
- Headquarters
- Building A, Macquarie Park, NSW, AU
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Michael C. Kavanagh
- Headquarters
- Building A, Macquarie Park, NSW, AU
Nanosonics Limited, together with its subsidiaries, operates as an infection prevention company in Australia and internationally.
The company engages in the manufacturing and distribution of the trophon ultrasound probe disinfector, and its associated consumables and accessories; and research, development, and commercialization of infection control and decontamination products and related technologies.
It provides trophon2, an ultrasound probe high level disinfection device; trophon EPR, a low temperature high level disinfection solution for intra-cavity ultrasound probes; and Nanosonics AuditPro, an infection control workflow compliance management solution.
Nanosonics Limited was incorporated in 2000 and is headquartered in Macquarie Park, Australia.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Nanosonics Limited, and the rating behind it. NNCSF last traded at $2.30, 46.9× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Nanosonics Limited. Starting points for Nanosonics Limited: P/E 46.9, EPS $0.06, beta 1.61 — an Medical - Instruments & Supplies name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Nanosonics Limited. Nanosonics Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Nanosonics Limited. Trailing twelve-month EPS for Nanosonics Limited stands at $0.06. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Nanosonics Limited. Nanosonics Limited has reported as a listed company since 2012. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Nanosonics Limited valued side by side against its closest peers. Nanosonics Limited is measured against Medical - Instruments & Supplies peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Nanosonics Limited, and how their positions are changing. At a $697.7M market value, institutional positions materially move Nanosonics Limited's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Nanosonics Limited executives and directors. Shares of Nanosonics Limited have traded between $2.14 and $3.30 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Nanosonics Limited. Nanosonics Limited is a $697.7M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Nanosonics Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Nanosonics Limited. Coverage tracks Nanosonics Limited within Medical - Instruments & Supplies (Healthcare). Press releases and market coverage, newest first.